Evidence map›Paper›PMID 30351423›Full record

ArticleSchizophrenia bulletin2019

The Global Functioning: Social and Role Scales-Further Validation in a Large Sample of Adolescents and Young Adults at Clinical High Risk for Psychosis.

Ricardo E Carrión, Andrea M Auther, Danielle McLaughlin, Ruth Olsen, Jean Addington, Carrie E Bearden, Kristin S Cadenhead, Tyrone D Cannon, Daniel H Mathalon, Thomas H McGlashan and 6 more

Open access · bronzeAbstract readMulticenter StudyValidation Study
In one paragraph

Article in Schizophrenia bulletin, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Effects of diazepam on hippocampal blood flow in people at clinical high risk for psychosis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. GABAMolecular psychiatry · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 2 countries.

Ricardo E CarriónDivision of Psychiatry Research, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY.
Andrea M AutherDivision of Psychiatry Research, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY.
Danielle McLaughlinDivision of Psychiatry Research, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY.
Ruth OlsenDivision of Psychiatry Research, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY.
Jean AddingtonHotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Calgary, AB, Canada.
Carrie E BeardenSemel Institute for Neuroscience and Human Behavior and Department of Psychology, University of California, Los Angeles, Los Angeles, CA.
Kristin S CadenheadDepartment of Psychiatry, University of California, San Diego, La Jolla, CA.
Tyrone D CannonDepartment of Psychology, Yale University, School of Medicine, New Haven, CT.
Daniel H MathalonDepartment of Psychiatry, University of California, San Francisco, CA.
Thomas H McGlashanDepartment of Psychiatry, Yale University, School of Medicine, New Haven, CT.
Diana O PerkinsDepartment of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Larry J SeidmanDepartment of Psychiatry, Harvard Medical School at Beth Israel Deaconess Medical Center and Massachusetts General Hospital, Boston, MA.
Ming T TsuangDepartment of Psychiatry, Harvard Medical School at Beth Israel Deaconess Medical Center and Massachusetts General Hospital, Boston, MA.
Elaine F WalkerDepartment of Psychology, Emory University, Atlanta, GA.
Scott W WoodsDepartment of Psychiatry, Yale University, School of Medicine, New Haven, CT.
Barbara A CornblattDivision of Psychiatry Research, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY.
Northwell Health · USYale University · USBeth Israel Deaconess Medical Center · USEmory University · USUniversity of Calgary · CAUniversity of California, Los Angeles · USUniversity of California San Diego · USUniversity of California, San Francisco · USUniversity of North Carolina at Chapel Hill · US

Funding

Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
STRESS AND EMOTIONAL REACTIVITYP50MH066286 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NUECHTERLEIN, KEITH H · 2003 to 2014
$18.6M
1/9 Predictors and Mechanisms of Conversion to PsychosisU01MH081902 · NIMH · YALE UNIVERSITY · PI CANNON, TYRONE D · 2008 to 2018
$12.4M
Vulnerability to Progression SchizophreniaP50MH080272 · NIMH · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WOO, TSUNGUNG · 2007 to 2011
$9.9M
5/9 Predictors and Mechanisms of Conversion to PsychosisU01MH082004 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PERKINS, DIANA O. · 2008 to 2018
$7.5M
Administrative Supplement Harmonization of At Risk Multisite Observational Networks for Youth(HARMONY)U01MH081928 · NIMH · BETH ISRAEL DEACONESS MEDICAL CENTER · PI STONE, WILLIAM SETH · 2008 to 2018
$7.1M
4/9-Predictors and Mechanisms of Conversion to PsychosisU01MH081857 · NIMH · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI CORNBLATT, BARBARA A. · 2008 to 2018
$6.2M
8/9 Predictors and Mechanisms of Conversion to PsychosisU01MH082022 · NIMH · YALE UNIVERSITY · PI WOODS, SCOTT W · 2008 to 2018
$6.0M
2/9 - Predictors and Mechanisms of Conversion to PsychosisU01MH081988 · NIMH · EMORY UNIVERSITY · PI WALKER, ELAINE FRAN · 2008 to 2018
$5.4M
"7/9" Predictors and Mechanisms of Conversion to PsychosisU01MH081984 · NIMH · UNIVERSITY OF CALGARY · PI ADDINGTON, JEAN M · 2008 to 2018
$4.2M
Functional Brain Abnormalities in the Schizophrenia ProdromeR01MH076989 · NIMH · YALE UNIVERSITY · PI MATHALON, DANIEL H · 2007 to 2014
$2.3M
NCATS NIH HHS UL1 TR001102NCATS NIH HHS UL1 TR001863NIMH NIH HHS P50 MH066286NIMH NIH HHS P50 MH080272NIMH NIH HHS R01 MH076989NIMH NIH HHS U01 MH081857NIMH NIH HHS U01 MH081902NIMH NIH HHS U01 MH081928NIMH NIH HHS U01 MH081984NIMH NIH HHS U01 MH081988NIMH NIH HHS U01 MH082004NIMH NIH HHS U01 MH082022
6 · The paper itself

Abstract

objectiveTraditional measures for assessing functioning with adult patients with schizophrenia have been shown to be insufficient for assessing the issues that occur in adolescents and young adults at clinical high risk (CHR) for psychosis. The current study provides an expanded validation of the Global Functioning: Social (GF:Social) and Role (GF:Role) scales developed specifically for use with CHR individuals and explores the reliability and accuracy of the ratings, the validity of the scores in comparison to other established clinical measures, stability of functioning over a 2-year period, and psychosis predictive ability.

methodsSeven hundred fifty-five CHR individuals and 277 healthy control (HC) participants completed the GF:Social and Role scales at baseline as part of the North American Prodrome Longitudinal Study (NAPLS2).

resultsInter-rater reliability and accuracy were high for both scales. Correlations between the GF scores and other established clinical measures demonstrated acceptable convergent and discriminant validity. In addition, GF:Social and Role scores were unrelated to positive symptoms. CHR participants showed large impairments in social and role functioning over 2-years, relative to the HCs, even after adjusting for age, IQ, and attenuated positive symptoms. Finally, social decline prior to baseline was more pronounced in CHR converters, relative to non-converters.

conclusionsThe GF scales can be administered in a large-scale multi-site study with excellent inter-rater reliability and accuracy. CHR individuals showed social and role functioning impairments over time that were not confounded by positive symptom severity levels. The results of this study demonstrate that social decline is a particularly effective predictor of conversion outcome.

Indexed as

Prodromal SymptomsAdolescentAdultFemaleHumansLongitudinal StudiesMalePsychiatric Status Rating ScalesPsychotic DisordersReproducibility of ResultsRiskSchizophreniaYoung AdultAdolescentCHRGlobal Functioning: RoleGlobal Functioning: SocialNAPLSProdromalscale validation

Identifiers

PMID30351423
PMCPMC6581127
OpenAlexW2896024746

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.